Clinical Trial Update: Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin) [Phase 3]

View source ↗

Summary

Phase 3 trial update showing the efficacy and safety of alirocumab versus placebo on top of maximally tolerated lipid-lowering therapy in adults with hyperchole…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Praluent (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolaemia | Phase 3 | Status: COMPLETED | Results posted: 2018-05-17